A New Option for Advanced Breast Cancer: Understanding Sacituzumab Govitecan

A new 2024 study in Frontiers in Oncology looked at sacituzumab govitecan, a targeted therapy for triple-negative breast cancer (TNBC)—a fast-growing cancer with fewer treatment options. Already FDA-approved, this drug continues to show promising results, even in real-world settings, for women who’v

A New Option for Advanced Breast Cancer: Understanding Sacituzumab Govitecan
Template for Youtube (9)

Read more